|
13 Nov 2017 |
NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model
|
|
12 Nov 2017 |
Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
|
|
12 Nov 2017 |
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
|
|
10 Nov 2017 |
Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
|
|
09 Nov 2017 |
Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
|
|
08 Nov 2017 |
Immunovaccine Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL
|
|
08 Nov 2017 |
Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer
|
|
08 Nov 2017 |
Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
|
|
08 Nov 2017 |
Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017
|
|
07 Nov 2017 |
Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
|
|
06 Nov 2017 |
BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
|
|
06 Nov 2017 |
SOTIO Completes Enrolment of Phase III VIABLE Study in Late Stage Prostate Cancer
|
|
02 Nov 2017 |
United Neuroscience Presents Data for Phase 2 Active Vaccine Program UB-311 at the Clinical Trials on Alzheimer's Disease 2017 Meeting
|
|
02 Nov 2017 |
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
|
|
30 Oct 2017 |
Vaxart Announces Positive Safety and Immunogenicity Results for Its Oral Norovirus Vaccine in a Phase 1b Clinical Study
|
|
30 Oct 2017 |
FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax™ in Patients with Advanced Breast Cancer
|
|
27 Oct 2017 |
CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors
|
|
26 Oct 2017 |
Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study
|
|
25 Oct 2017 |
Alopexx completes first-in-man trial of its novel, broad-spectrum anti-microbial vaccine
|
|
24 Oct 2017 |
Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
|
|
23 Oct 2017 |
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
|
|
21 Oct 2017 |
DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
|
|
18 Oct 2017 |
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
|
|
17 Oct 2017 |
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
|
|
17 Oct 2017 |
Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
|
